OrthoPediatrics Corp. (NASDAQ:KIDS) Given Consensus Rating of “Moderate Buy” by Analysts

OrthoPediatrics Corp. (NASDAQ:KIDS) has been assigned a consensus rating of “Moderate Buy” from the eleven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $24.4444.

KIDS has been the topic of several analyst reports. Truist Financial set a $17.00 price objective on OrthoPediatrics in a research report on Friday, May 1st. Canaccord Genuity Group set a $25.00 price objective on OrthoPediatrics in a research report on Friday, April 24th. Wall Street Zen raised OrthoPediatrics from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. BTIG Research reaffirmed a “buy” rating and issued a $24.00 price objective on shares of OrthoPediatrics in a research report on Friday, May 1st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OrthoPediatrics in a research report on Tuesday, April 21st.

OrthoPediatrics Stock Performance

KIDS stock opened at $17.83 on Friday. The stock has a market capitalization of $457.87 million, a PE ratio of -10.61 and a beta of 1.03. OrthoPediatrics has a 12-month low of $14.42 and a 12-month high of $23.70. The company has a current ratio of 5.21, a quick ratio of 2.37 and a debt-to-equity ratio of 0.29. The stock’s 50 day simple moving average is $17.09 and its 200 day simple moving average is $17.43.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings data on Thursday, April 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.04. The business had revenue of $59.36 million for the quarter, compared to analysts’ expectations of $58.29 million. OrthoPediatrics had a negative return on equity of 7.01% and a negative net margin of 16.31%. As a group, research analysts forecast that OrthoPediatrics will post -1.13 earnings per share for the current fiscal year.

Insider Buying and Selling at OrthoPediatrics

In other OrthoPediatrics news, insider Joseph W. Hauser sold 8,596 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $17.25, for a total transaction of $148,281.00. Following the completion of the sale, the insider directly owned 194,767 shares in the company, valued at approximately $3,359,730.75. The trade was a 4.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Gregory A. Odle sold 8,433 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $17.25, for a total transaction of $145,469.25. Following the sale, the insider owned 187,735 shares of the company’s stock, valued at approximately $3,238,428.75. This represents a 4.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 58,171 shares of company stock worth $1,003,450. 32.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On OrthoPediatrics

A number of hedge funds have recently added to or reduced their stakes in KIDS. Russell Investments Group Ltd. raised its stake in OrthoPediatrics by 433.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after buying an additional 1,139 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in OrthoPediatrics by 5,226.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock valued at $46,000 after buying an additional 2,561 shares during the last quarter. Caption Management LLC purchased a new stake in OrthoPediatrics during the 3rd quarter valued at $54,000. BNP Paribas Financial Markets raised its stake in OrthoPediatrics by 60.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock valued at $61,000 after buying an additional 1,235 shares during the last quarter. Finally, State of Wyoming raised its stake in OrthoPediatrics by 189.7% during the 4th quarter. State of Wyoming now owns 6,822 shares of the company’s stock valued at $121,000 after buying an additional 4,467 shares during the last quarter. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.